Officially announced today by ActivX Biosciences Inc, La Jolla (CA, USA), findings published ahead of print this month in Molecular Cancer Therapeutics* represent an important forward step in better predicting which patients would be most likely to benefit from treatment with CDK4/6 inhibitors.

First authored by Jennifer Green, Senior Research Scientist at ActivX Biosciences, this study was carried in collaboration with VHIO’s Experimental Therapeutics Group directed by Violeta Serra, and marks progress towards more precisely gauging the sensitivity or resistance of patients to these particular anti-cancer therapies.

To disover more, please see  ActivX Biosciences’ news release below.

###

*Green JL, Okerberg ES, Sejd J, Palafox M, Monserrat L, Alemayehu S, Wu J, Sykes M, Aban A, Serra V, Nomanbhoy T. Direct CDKN2 modulation of CDK4 alters target engagement of CDK4 inhibitor drugs.

Mol Cancer Ther. 2019 Mar 5. pii: molcanther.0755.2018. doi: 10.1158/1535-7163.MCT-18-0755. [Epub ahead of print]

 

Source: ActivX Biosciences

ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients

ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces a report published in a high profile, peer-reviewed journal, Molecular Cancer Therapeutics, proposing the molecular mechanism determining the sensitivity or resistance to treatment with CDK4/6 inhibitors.

The CDK4/6 inhibitors palbociclib (Ibrance®, Pfizer), ribociclib (Kisqali®, Novartis) and abemaciclib (Verzenio®, Lilly) are approved for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. While these drugs have demonstrated clinical efficacy, there remains a need for biomarkers to predict patient response as well as to extend the use of these drugs beyond ER-positive breast cancer. Scientists at ActivX Biosciences, and their collaborators at Vall d’Hebron Institute of Oncology (VHIO), Barcelona, showed that high levels of p16/CDKN2A, an endogenous regulator of CDK4/6, could serve as a biomarker to identify patients unlikely to respond to CDK4/6 inhibitors, thus sparing them from unnecessary treatment.

Using the KiNativ® platform, the authors assessed CDK4/6 target engagement in a panel of cell lines with known alterations in p16-CDK4 binding and showed that the interaction between p16 and CDK4 limits target engagement by CDK4/6 inhibitor drugs. Further research demonstrated that high levels of p16 were correlated with a lack of biological response in a diverse panel of cell lines that included the highly aggressive triple-negative breast cancer subtype.

“We believe our findings will help define patient selection criteria for future clinical trials and extend the therapeutic benefits of these important drugs to patients with other types of cancer,” commented Jennifer Green, lead author of the study. “Identifying mechanisms for cell type-specific target engagement showcases the power of our technology. I’m excited to see what other examples are uncovered as the method is more broadly utilized.”

###

About ActivX Biosciences, Inc.

ActivX Biosciences, Inc. (www.activx.com) located in La Jolla, California, is a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co. Ltd, and has drug discovery and proteomics technology capabilities. The company applies proprietary chemical technologies and high-throughput protein analysis to the drug discovery and development process. By focusing on functional proteins, ActivX® addresses disease mechanisms directly, in contrast to approaches such as expression profiling, in which the measured analyte is several steps removed from the site of drug action. ActivX® and its partners are using ActivX’s proprietary technology to address critical challenges in drug discovery, including selectivity profiling of candidate drug molecules across whole protein families in biological samples to guide their medicinal chemistry efforts, identifying novel drug targets and biomarkers, and characterizing off-target activities of candidate and established drugs to understand the basis of their efficacy and/or toxicity.